HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages.

Abstract
Synthetic lipopeptides based on bacterial lipoprotein are efficient activators for monocytes/macrophages inducing the release of interleukin (IL)-1, IL-6, tumour necrosis factor-alpha (TNF-alpha), reactive oxygen/nitrogen intermediates, and the translocation of nuclear factor kappaB (NFkappaB). In this report we investigate the signal transduction pathways involved in leucocyte activation by the synthetic lipopeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-(R)-cysteinyl-seryl-(lysyl)3-lysine (P3CSK4). We show that P3CSK4 activates mitogen-activated protein (MAP)-kinases ERK1/2 and MAP kinase (MAPK)-kinases MEK1/2 in bone-marrow-derived macrophages (BMDM) and in the macrophage cell line RAW 264.7. Additionally, we could detect differences between the P3CSK4 and lipopolysaccharide (LPS)-induced phosphorylation of MAP kinases: Different levels in phosphorylation were found both in kinetics and dose-response using RAW 264.7 cells or BMDM from BALB/c and LPS responder mice (C57BL/10ScSn) or LPS non-responder mice (C57BL/10ScCr). The lipopeptide activated the MAPK-signalling cascade in both LPS responder and non-responder macrophages, whereas LPS induced the MAPK signalling pathway only in macrophages derived from LPS responder mice. An approximately 70% decrease of lipopeptide induced NFkappaB translocation and an about 50% reduction of nitric oxide (NO) release was observed in the presence of anti-CD14. These data correspond to the reduction of phosphorylation of ERK1/2 after stimulation with P3CSK4 in the presence of anti-CD14 antibodies. Inhibition of MEK1/2 by PD98059 completely reduced the lipopeptide-induced phosphorylation of ERK1/2 indicating that MEK1/2 are solely responsible for the phosphorylation of the downstream-located MAP kinases ERK1/2.
AuthorsM R Müller, S D Pfannes, M Ayoub, P Hoffmann, W G Bessler, K Mittenbühler
JournalImmunology (Immunology) Vol. 103 Issue 1 Pg. 49-60 (May 2001) ISSN: 0019-2805 [Print] England
PMID11380692 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Drosophila Proteins
  • Enzyme Inhibitors
  • Flavonoids
  • Lipopolysaccharide Receptors
  • Lipopolysaccharides
  • Lipoproteins
  • Membrane Glycoproteins
  • NF-kappa B
  • Receptors, Cell Surface
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine
  • Nitric Oxide
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Topics
  • Animals
  • Bone Marrow (immunology)
  • Cell Line
  • Drosophila Proteins
  • Enzyme Inhibitors (pharmacology)
  • Flavonoids (pharmacology)
  • Lipopolysaccharide Receptors (immunology)
  • Lipopolysaccharides (immunology)
  • Lipoproteins (immunology)
  • Macrophage Activation (immunology)
  • Membrane Glycoproteins (immunology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinase 1 (immunology)
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinase Kinases (metabolism)
  • Mitogen-Activated Protein Kinases (immunology, metabolism)
  • NF-kappa B (genetics)
  • Nitric Oxide (metabolism)
  • Phosphorylation
  • Receptors, Cell Surface (immunology)
  • Signal Transduction (immunology)
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Translocation, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: